Key Takeaways
- • PolyPeptide Group has advanced its sale process by shortlisting EQT AB and IDG Capital as lead bidders, with US-based Altaris remaining engaged in discussions for the Swiss contract drug manufacturer.
- • The company carries a current market valuation of approximately $1.6 billion following a recent share price rally, though remains below valuations from several years prior.
- • PolyPeptide confirmed in April that it was reviewing strategic options; the bidding process is ongoing with no formal offers submitted and discussions continuing through due diligence phases.
- • Founded in 1993, PolyPeptide operates manufacturing facilities across Europe, the United States, and India, specializing in peptide-based therapies for metabolic, oncological, cardiovascular, and neurological conditions serving global pharmaceutical clients.
- • A successful transaction would align with recent healthcare sector consolidation in Switzerland, including Lone Star Funds' acquisition of a Lonza Group unit and SK Capital Partners' majority stake purchase in Swixx Biopharma.
Summary
PolyPeptide Group, the Swiss contract drug manufacturer controlled by billionaire Frederik Paulsen, has narrowed its buyer field to EQT AB and IDG Capital in an advancing auction process, according to Bloomberg. The company, which disclosed in April that it was reviewing strategic options following earlier takeover interest, continues to engage US-based Altaris alongside the two shortlisted private equity firms. No formal offers have been submitted as bidders remain in due diligence and financial review phases.
The company carries a market valuation of approximately $1.6 billion following recent share price gains, though current valuations remain below levels achieved in prior years. Founded in 1993, PolyPeptide develops peptide-based pharmaceutical therapies targeting metabolic, oncological, cardiovascular, and neurological conditions, operating manufacturing facilities across Europe, the United States, and India while servicing a global pharmaceutical client base. The business operates as a specialized contract manufacturer in a sector characterized by consolidation and strategic repositioning.
EQT, the European private equity firm, has demonstrated active engagement in healthcare and industrial carve-out transactions across Europe, while IDG Capital brings experience across global consumer and lifestyle brand investments. The sale process reflects steady healthcare-sector private equity activity in Switzerland, which has recently seen transactions including Lone Star Funds' acquisition of a Lonza Group unit and SK Capital Partners' purchase of a majority stake in Swixx Biopharma. Management has indicated no certainty the strategic review process will conclude in a transaction, with ongoing discussions subject to customary closing conditions and regulatory approvals.
The company carries a market valuation of approximately $1.6 billion following recent share price gains, though current valuations remain below levels achieved in prior years. Founded in 1993, PolyPeptide develops peptide-based pharmaceutical therapies targeting metabolic, oncological, cardiovascular, and neurological conditions, operating manufacturing facilities across Europe, the United States, and India while servicing a global pharmaceutical client base. The business operates as a specialized contract manufacturer in a sector characterized by consolidation and strategic repositioning.
EQT, the European private equity firm, has demonstrated active engagement in healthcare and industrial carve-out transactions across Europe, while IDG Capital brings experience across global consumer and lifestyle brand investments. The sale process reflects steady healthcare-sector private equity activity in Switzerland, which has recently seen transactions including Lone Star Funds' acquisition of a Lonza Group unit and SK Capital Partners' purchase of a majority stake in Swixx Biopharma. Management has indicated no certainty the strategic review process will conclude in a transaction, with ongoing discussions subject to customary closing conditions and regulatory approvals.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.